GLG News Analyses of the following article:
A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT
Published at: meeting.ascopubs.org
-
Gleevec shows promise as targeted melanoma treatment
July 27, 2009
Gleevec (Imatinib), a target specific cancer treatment drug against KIT oncogene mutations, shows early evidence of efficacy in treating melanomas with susceptible genetic mutations, further support for a personalized medicine, targeted therapy, approach to treating melanoma and cancers in general.
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.